الرئيسية › سرطان الثدي › ميزوري › Kansas City
التجارب السريرية لـ سرطان الثدي في Kansas City، MO
34 دراسات لـ سرطان الثدي تبحث عن مشاركين في مواقع داخل وحول Kansas City (ضمن نطاق 30 ميلًا تقريبًا). افتح الدراسة لمعرفة من يمكنه المشاركة وكيفية التواصل مع فريق الدراسة.
النص الرسمي للدراسة (بالإنجليزية)
تبحث عن مشاركين لدراسة؟ أبرزها في أعلى الصفحة — $99 لمدة 30 يومًا →
The Vanguard Study: Testing a New Way to Screen for Cancer
جارٍ التسجيلمرحباً بالمتطوعين الأصحاء
- Saint Luke's Hospital of Kansas City, Kansas City
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
جارٍ التسجيلالمرحلة 3
- University of Kansas Cancer Center, Westwood · على بُعد 5 ميل
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
جارٍ التسجيلالمرحلة 3
- HCA Midwest Division, Kansas City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
جارٍ التسجيلدراسة رصديةمرحباً بالمتطوعين الأصحاء
- Kansas City Veterans Affairs Medical Center, Kansas City
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
جارٍ التسجيلالمرحلة 2
- Saint Luke's Cancer Institute, Kansas City
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- St. Lukes Hospital of Kansas City, Kansas City
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
جارٍ التسجيلالمرحلة 3
- Saint Luke's Cancer Institute ( Site 0027), Kansas City
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
جارٍ التسجيلالمرحلة 3
- The University of Kansas Cancer Center, Westwood · على بُعد 5 ميل
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
جارٍ التسجيلالمرحلة 3
- Saint Luke's Cancer Institute ( Site 0059), Kansas City
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
جارٍ التسجيلالمرحلة 3
- Clinical Trial Site, Kansas City
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
جارٍ التسجيلالمرحلة 3
- Saint Luke's Cancer Institute, Kansas City
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
جارٍ التسجيلالمرحلة 1/2
- Saint Luke's Hospital of Kansas City, Kansas City
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
جارٍ التسجيلالمرحلة 3
- Saint Luke's Hospital of Kansas City, Kansas City
A Phase 1/1b Study of IAM1363 in HER2 Cancers
جارٍ التسجيلالمرحلة 1
- Saint Luke's Cancer Institute, Kansas City
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
جارٍ التسجيلالمرحلة 2
- HCA Midwest Division, Kansas City
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
جارٍ التسجيلالمرحلة 3
- HCA Midwest Health, Kansas City
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
جارٍ التسجيلالمرحلة 3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- و 1 أخرى
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
جارٍ التسجيلدراسة رصديةمرحباً بالمتطوعين الأصحاء
- Universtiy Health, Kansas City
- KCCC South, Kansas City
- Research Medical Center, Kansas City
- و 2 أخرى
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
جارٍ التسجيلالمرحلة 3
- University of Kansas Cancer Center - North, Kansas City
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
جارٍ التسجيلالمرحلة 2/3
- Saint Luke's Cancer Institute, Kansas City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
جارٍ التسجيلالمرحلة 1/2
- University of Kansas Medical Center (KUMC), Westwood · على بُعد 5 ميل
HER2-positive Breast Cancer Registry
جارٍ التسجيلدراسة رصدية
- The University of Kansas Cancer Center, Westwood · على بُعد 5 ميل
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Saint Luke's Cancer Institute, Kansas City
Integrated Cancer Repository for Cancer Research
جارٍ التسجيلدراسة رصديةمرحباً بالمتطوعين الأصحاء
- Saint Luke's Cancer Institute, East, Kansas City
- Saint Luke's Cancer Institute, Kansas City
- Saint Luke's Cancer Institute, Kansas City North, Kansas City
- و 1 أخرى
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
جارٍ التسجيلالمرحلة 3
- Saint Luke's Cancer Institute, Kansas City
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
جارٍ التسجيلالمرحلة 3
- Saint Luke's Cancer Institute, Kansas City
- The University of Kansas Cancer Center, Westwood · على بُعد 5 ميل
Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
جارٍ التسجيلالمرحلة 2
- The University of Kansas Cancer Center - North, Kansas City
- KUCC - Briarcliff, Westwood · على بُعد 5 ميل
- KUCC - Olathe, Westwood · على بُعد 5 ميل
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
جارٍ التسجيلالمرحلة 3
- Saint Luke's Hospital of Kansas City, Kansas City
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
جارٍ التسجيلالمرحلة 3
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City · على بُعد 2 ميل
- و 1 أخرى
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
جارٍ التسجيلالمرحلة 1/2
- The University of Kansas Cancer Center, Westwood · على بُعد 5 ميل
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
جارٍ التسجيلدراسة رصدية
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- و 1 أخرى
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
جارٍ التسجيلدراسة رصدية
- Saint Luke's Hospital of Kansas City, Kansas City
- University of Kansas Cancer Center, Westwood · على بُعد 5 ميل
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
جارٍ التسجيلدراسة رصدية
- Massive Bio SYNERGY-AI site, Kansas City
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
جارٍ التسجيلالمرحلة 3
- Truman Medical Centers, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City · على بُعد 2 ميل
- و 1 أخرى
تجارب سرطان الثدي في مدن أخرى
- New York City, NY136 دراسات
- Houston, TX126 دراسات
- Boston, MA112 دراسات
- Nashville, TN81 دراسات
- Los Angeles, CA73 دراسات
- Edison, NJ68 دراسات
- St. Louis, MO64 دراسات
- Queens, NY64 دراسات
- Durham, NC64 دراسات
- Chicago, IL59 دراسات
- Philadelphia, PA56 دراسات
- Dallas, TX55 دراسات
دراسات أخرى في Kansas City
- سرطان الرئة غير صغير الخلايا31 دراسات
- قصور القلب25 دراسات
- السرطان (جميع الأنواع)21 دراسات
- سرطان الرئة19 دراسات
- سرطان القولون والمستقيم16 دراسات
- السرطان النقيلي15 دراسات
- ابيضاض الدم النقوي الحاد15 دراسات
- سرطان البروستاتا14 دراسات
- سرطان المبيض11 دراسات
- السمنة11 دراسات
- السكري من النوع الثاني11 دراسات
- أمراض القلب والأوعية الدموية11 دراسات
من ClinicalTrials.gov، البيانات مستخرجة في 06/10/2026. كل دراسة تحدد معايير أهليتها الخاصة؛ فريق الدراسة هو من يحدد من يمكنه المشاركة.